Brief: Coya Therapeutics Announces Successful Pre-Ind And Type C Meetings With The FDA
05/01/2024 13:58
Jan 5 (Reuters) - Coya Therapeutics Inc COYA.O :
* COYA THERAPEUTICS ANNOUNCES SUCCESSFUL PRE-IND AND TYPE C
MEETINGS WITH THE FDA TO ADVANCE THE DEVELOPMENT OF COYA 302 FOR
TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
* COYA HAS A CLEAR PATH TOWARDS SUBMISSION OF IND
APPLICATION TO
FDA IN Q2 OF 2024
* WITH RECENT OUT-LICENSING TRANSACTION AND PRIVATE
PLACEMENT
TRANSACTION SECURING COYA A CASH RUNWAY INTO 2026
Source text for Eikon: ID:nBw68Rt2xa
Further company coverage: COYA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Coya Therapeutics
See all newsCoya Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Coya Therapeutics Q2 net loss widens as R&D costs rise
Coya Therapeutics Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: Coya Therapeutics Entered Into Sales Agreement, May Offer And Sell From Time To Time Shares Of Co's Common Stock For Up To $30 Million
Brief: Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation For Coya 302 For The Treatment Of Amyotrophic Lateral Sclerosis (ALS)